1月26日， 阳光诺和 跌5.05%，截至发稿，报69.15元/股，成交9956.56万元，换手率1.26%，总市值 77.45亿元。 资料显示，北京阳光诺和药物研究股份有限公司位于北京市昌平区科技园区双营西路79号院7号楼，成 立日期2009年3月9日，上市日期2021年6月21日，公司主营业务涉及 仿制药 开发、一致性评价及 创新 药 开发等方面的 综合 研发服务,服务内容主要包括药学研究、临床试验和生物分析。主营业务收入构成 为：CRO业务99.91%，其他(补充)0.09%。 从基金十大重仓股角度 数据显示，光大保德信基金旗下1只基金重仓阳光诺和。光大保德信健康优加混合A（012284）四季度 减持8.37万股，持有股数34.39万股，占基金净值比例为2.8%，位居第九大重仓股。根据测算，今日浮 亏损失约126.56万元。 光大保德信健康优加混合A（012284）成立日期2021年8月5日，最新规模7.61亿。今年以来收益 5.95%，同类排名4476/9003；近一年收益38.27%，同类排名3491/8185；成立以来亏损16.51%。 光大保德信健康优加混合A（012284）基金经理为徐晓杰。 ...

Core Viewpoint - The AI Fund Everbright Prudential Dividend Mixed A (360005) reported a profit of 10.48 million yuan for Q2 2025, with a net asset value growth rate of 4.05% during the period [3][17]. Fund Performance - As of July 18, the fund's unit net value was 1.839 yuan, with a one-year return of 6.53%, ranking 521 out of 601 comparable funds [3][4]. - The fund's three-month return was 8.50%, ranking 402 out of 607, and the six-month return was 9.87%, ranking 348 out of 607 [4]. - Over the past three years, the fund's return was -11.71%, ranking 228 out of 468 [4]. Risk Metrics - The fund's Sharpe ratio over the past three years was -0.1408, ranking 341 out of 468 [10]. - The maximum drawdown over the past three years was 29.06%, with the largest single-quarter drawdown occurring in Q1 2021 at 17.55% [12]. Fund Holdings - As of Q2 2025, the fund's top ten holdings included Kelun Pharmaceutical, Zhaoyi Innovation, Bank of China, CITIC Bank, Huahai Pharmaceutical, China Construction Bank, Ningbo Bank, Yangtze Power, China Shenhua, and Chongqing Rural Commercial Bank [21]. - The average stock position over the past three years was 79.12%, compared to the industry average of 85.36% [15].